Insulin degludec: Overview of a novel ultra long-acting basal insulin

Insulin degludec: Overview of a novel ultra long-acting basal insulin

Show other versions (1)

All the basal insulin products currently available have suboptimal pharmacokinetic (PK) properties, with none reliably providing a reproducible and peakless pharmacodynamic (PD) effect that endures over 24 h from once-daily dosing. Insulin degludec is a novel acylated basal insulin with a unique mec...

Full description

Bibliographic Details
Main Authors:	Gough, S, Harris, S, Woo, V, Davies, M
Format:	Journal article
Published:	2013

Similar Items

Insulin degludec: overview of a novel ultra long-acting basal insulin.
by: Gough, S, et al.
Published: (2013)

Insulin degludec: A novel ultra-acting basal insulin: Potential usefulness in hospitalized patients
by: Sukhminder Jit Singh Bajwa, et al.
Published: (2015-01-01)

Degludec insulin: A novel basal insulin
by: Sanjay Kalra, et al.
Published: (2011-01-01)

Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-07-01)

Efficacy and safety of ultra-long-acting insulin degludec
by: Ammar Wakil, et al.
Published: (2012-04-01)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
by: Sami N. Nasrallah, et al.
Published: (2012-04-01)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
by: Sami N. Nasrallah, et al.
Published: (2012-01-01)

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
by: Wang F, et al.
Published: (2012-07-01)

Insulin degludec
by: Vishakha V Jain, et al.
Published: (2013-01-01)

Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
by: Marina Vladimirovna Shestakova, et al.
Published: (2015-12-01)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
by: Shinje Moon, et al.
Published: (2021-09-01)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
by: Hongzhong Liu, et al.
Published: (2022-04-01)

Pediatric diabetes: Potential for insulin degludec
by: Sanjay Kalra, et al.
Published: (2014-01-01)

THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT
by: M. F. Kalashnikova, et al.
Published: (2016-12-01)

The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
by: M. V. Shestakova, et al.
Published: (2021-07-01)

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
by: Han Na Jang, et al.
Published: (2019-12-01)

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
by: Thuillier P, et al.
Published: (2015-10-01)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
by: Aye MM, et al.
Published: (2014-04-01)

Practical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia
by: Siew Pheng Chan, et al.
Published: (2023-05-01)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
by: Kyu Yong Cho, et al.
Published: (2020-08-01)

The use of long-acting insulin degludec in adult patients with type 2 diabetes mellitus in real clinical practice in Russia
by: G. R. Galstyan
Published: (2023-02-01)

A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300
by: Oppel B.W. Greeff, et al.
Published: (2018-08-01)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements
by: Scott M. Pearson, et al.
Published: (2018-04-01)

Insulin degludec aspart: One-year real world experience
by: Sanjay Kalra, et al.
Published: (2016-01-01)

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
by: Meneghini, L, et al.
Published: (2013)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
by: Qiong Luo, et al.
Published: (2022-10-01)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
by: Mizuho Yamabe
Published: (2019-11-01)

Low fasting glucose‐to‐estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes
by: Han Na Jang, et al.
Published: (2022-01-01)

Comparing time to intensification between insulin degludec/insulin aspart and insulin glargine: A single-center experience from India
by: Rajiv Kovil
Published: (2022-01-01)

Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
by: Junko Oya, et al.
Published: (2021-11-01)

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
by: Ratner, R, et al.
Published: (2013)

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-analysis of phase 3 trials
by: Ratner, R, et al.
Published: (2013)

Use of insulin degludec in pregnancy: two case reports and a literature review
by: E. Sprio, et al.
Published: (2020-11-01)

The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus
by: I. N. Dyakov, et al.
Published: (2021-02-01)

The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
by: Sarah J. Glastras, et al.
Published: (2020-04-01)

Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
by: Tevfik Demir, et al.
Published: (2021-03-01)

Efficacy and safety of insulin degludec in renal transplant recipients with pre-existing diabetes
by: Debmalya Sanyal, et al.
Published: (2021-03-01)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
by: Minze MG, et al.
Published: (2016-03-01)